Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
October 30, 2024 at 06:50 AM EDT
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.